As of September 30, 2023, Ocuphire had cash and cash equivalents of approximately $42.4 million. Based on current projections, management believes the present cash on hand will be sufficient to fund operations into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OCUP:
- Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
- Is OCUP a Buy, Before Earnings?
- Ocuphire Pharma announces end-of-phase2 meeting with FDA for APX3330
- Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ocuphire Pharma appoints Magrath as CEO, Director